still
daili qd mg fail meet primari endpoint week
stage improv fibrosi without worsen nash selonsertib safe
monday februari market close gilead report top-lin result
phase studi selonsertib inhibitor patient compens
cirrhosi due nonalcohol steatohepat nash dose selonsertib mg
gener well-toler consist previou studi data
evalu nash patient show patient treat selonsertib achiev
stage improv fibrosi patient mg vs placebo
patient mg vs placebo versu patient receiv placebo note
expect low selonsertib previous evalu
patient previou phase ii studi conduct patient
fibrosi regress demonstr dose-depend manner small number
patient cirrhosi stage nash advanc version diseas compris
much less inflamm marker littl remain adipos tissu
estim ascrib peak sale selonsertib billion
billion previous model chang led decreas valuat
selonsertib await result studi evalu selonsertib
bridg fibrosi expect first half failur
disappoint still chanc selonsertib work base higher
inflammatori state stage compar prior phase ii data view
remov sale estim model lower probabl
success studi lead lower fair valu
return equiti ttm
gilead research-bas biotechnolog compani focus develop therapi treatment life-
threaten diseas gilead leader hiv/aid therapeut recent hcv also
larg product portfolio includ therapeut liver cardiovascular inflammatori respiratori diseas
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
maintain outperform rate lower fair valu estim base lower
probabl success selonsertib exhibit model continu recogn rel flat
year return growth dcf analys hiv hcv franchis lead valuat
per share respect two late stage asset valu filgotinib per share probabl success
rheumatoid arthriti probabl success ulcer coliti crohn diseas valu
selonsertib per share advanc nash probabl success addit
valu yescarta next-gener product candid per share includ per share net cash year-end
deriv fair valu estim gilead share
risk outperform thesi includ compani depend hiv franchis repres fundament
concentr risk investor magnitud speed declin hcv franchis continu pipelin expans
cellular therapi clinic risk filgotinib selonsertib phase studi pipelin asset
drugpeak sale stage ofdevelopmentestimatedlaunch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuehiv phase phase year-end present valu addit loss fair includ cost directli relat program abovesourc william blair estimatesexhibit scienc inc fair valu import disclosur
